A case–control study to assess the effectiveness of  pertussis vaccination during pregnancy on newborns,  Valencian community, Spain, 1 March 2015 to 29  February 2016 by Bellido Blasco, Juan Bautista et al.
1www.eurosurveillance.org
Research article 
A case–control study to assess the effectiveness of 
pertussis vaccination during pregnancy on newborns, 
Valencian community, Spain, 1 March 2015 to 29 
February 2016
J Bellido-Blasco 1 2 3 , S Guiral-Rodrigo ⁴ , A Míguez-Santiyán ⁵ , A Salazar-Cifre ⁵ , F González-Morán 4 
1. Epidemiology Department. Public Health Centre of Castelló (DGSP), Castelló, Spain
2. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
3. Universitat Jaume I (UJI), Castelló, Spain
4. Surveillance and Epidemiologic Control Unit, Public Health Directorate, Regional Government of Valencia, Spain
5. Epidemiology Department. Public Health Centre of València (DGSP), València, Spain
Correspondence: Antonio Salazar (salazar_ant@gva.es)
Citation style for this article: 
Bellido-Blasco J, Guiral-Rodrigo S, Míguez-Santiyán A, Salazar-Cifre A, González-Morán F. A case–control study to assess the effectiveness of pertussis vaccination 
during pregnancy on newborns, Valencian community, Spain, 1 March 2015 to 29 February 2016. Euro Surveill. 2017;22(22):pii=30545. DOI: http://dx.doi.
org/10.2807/1560-7917.ES.2017.22.22.30545 
Article submitted on 10 April 2017 / accepted on 25 April 2017 / published on 01 June 2017
In the Valencian Community (Spain), the programme 
of maternal pertussis vaccination during pregnancy 
started in January 2015. The objective of this study 
was to estimate in this region the vaccine effective-
ness (VE) in protecting newborns against laboratory-
confirmed pertussis infection. A matched case–control 
study was undertaken in the period between 1 March 
2015 and 29 February 2016. Twenty-two cases and 66 
controls (+/− 15 days of age difference) were included 
in the study. Cases were non-vaccinated infants < 3 
months of age at disease onset testing positive for 
pertussis by real-time PCR. For every case three unvac-
cinated controls were selected. Odds ratios (OR) were 
calculated by multiple conditional logistic regression 
for association between maternal vaccination and 
infant pertussis. Other children in the household, as 
well as mother- and environmental covariates were 
taken into account. The VE was calculated as 1 − OR. 
Mothers of five cases (23%) and of 41 controls (62%) 
were vaccinated during pregnancy. The adjusted VE 
was 90.9% (95% confidence interval (CI): 56.6 to 98.1). 
The only covariate in the final model was breastfeed-
ing (protective effect). Our study provides evidence in 
favour of pertussis vaccination programmes for preg-
nant women in order to prevent whooping cough in 
infants aged less than 3 months.
Introduction
Pertussis persists as an infection of global public 
health importance. Many countries with long-standing 
vaccination programmes have reported a resurgence 
of pertussis, despite sustained high vaccine coverage 
[1-4].
In October 2012, the United States and United Kingdom 
became the first countries recommending that pertus-
sis-containing vaccine (tetanus, diphtheria, acellular 
pertussis (Tdap)) should be routinely offered to women 
in every pregnancy [5]. Tdap immunisation during ges-
tation is thought to augment the transplacental trans-
fer of pertussis-specific IgG [6]. This process may be 
affected by multiple factors including placental integ-
rity, total IgG concentration in maternal blood, time of 
immunisation, and time elapsed between immunisa-
tion and delivery.
Although there is no generally accepted level of per-
tussis-specific antibodies that would confer protection 
against infection [7], results reported from some coun-
tries since 2012 [8], on maternal pertussis immunisa-
tion at any time before or after pregnancy improving 
protection of very young children are encouraging. On 
the other hand, we do not have a correlate for protec-
tion for all vaccines, but can still demonstrate that they 
offer protection in field studies.
Since January 2015, the Valencian Community’s 
General Directorate of Public Health has recommended 
that pregnant women be offered a single dose of Tdap 
vaccine between 27 and 36 weeks of gestation, as a 
measure to temporarily protect infants in a period fol-
lowing birth and before these infants receive vaccina-
tion according to the schedule.
The main objective of this study was to estimate, in our 
region, the pertussis vaccine effectiveness (VE), when 
given to pregnant women, in protecting newborns 
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against laboratory-confirmed pertussis infection using 
a case–control study design.
Methods
Setting and study
Whooping cough is a notifiable disease in Spain. 
Notified cases do not necessarily have to be PCR lab-
oratory-confirmed, but confirmation by this method 
frequent. The current recommended infant schedule 
is: one dose of vaccine at 2 months-old, a second at 
4 months-old, a third at 6 months-old, and a fourth at 
18 months-old, with a final dose between the age of 5 
and 9 years. 
A prospective matched case–control study was car-
ried out through one year in a dynamic population. 
The study covered the whole territory of the Valencian 
Community (5 million inhabitants). 
Participants
All unvaccinated pertussis infants notified in the 
Valencian Community during the study period had 
been PCR-laboratory-confirmed. Cases were defined as 
unvaccinated infants less than 3 months-old, with per-
tussis microbiological confirmation by PCR. They were 
identified from a computerised mandatory notification 
system (AVE, Análisis de Vigilancia Epidemiológica) 
from 1 March 2015 until 29 February 2016. 
For every case three paired controls by age, with an 
age difference of less than 15 days, were included. 
Two of these three controls were infants who had con-
sulted the same paediatrician/family doctor practice 
as the case, and had presented to this practice either 
for a routine assessment or for a consultation due to 
ill-health. In order to avoid a possible overmatching in 
this setting, we selected a third control fulfilling the 
same criteria as the prior described controls, but from 
the maternity clinic where the case was born. Like the 
cases, controls were unvaccinated. Absence of whoop-
ing cough in controls was confirmed by checking clini-
cal records and by phone interviews with parents and 
paediatricians/family doctors. The children with any 
previous episodes of cough and bronchiolitis were 
excluded. 
Sample size
Taking as reference, 17% vaccination of the mothers 
among the cases [9], with a vaccine effectiveness of 
90% and a statistical power of 80%, the number of 
children needed for the study was 52 (13 cases and 39 
controls).
Information on participants
Information from cases was obtained from paediatri-
cians and parents either by face-to-face interviews 
during the period of their hospitalisation, or by phone, 
for cases who were not hospitalised, to avoid misclas-
sification. Information from matched controls was 
collected less than 5 days after case notification by 
trained nurses. A questionnaire elaborated specifically 
for the study was used to collect medical information 
and exposure risks from child, mother and environ-
ment in both groups.
Presence or absence of disease in the newborn and vac-
cination of the mother during the pregnancy were the 
main variables. The vaccination status of all mothers in 
the study was verified in the Register of Vaccinations 
of the Valencian Community; we collected vaccination 
dates. Using the same register, it was also checked 
that none of the cases and controls were vaccinated.
Case–control study
Risk covariates were classified in three groups: (i) 
Children covariates: date of birth, age in days, sex, 
city of residence, birth weight, Apgar test, breastfeed-
ing; (ii) Mothers’ covariates: age, pregnancy week of 
the childbirth, precedent of whooping cough disease 
Figure 1
Cases of pertussis among newborns, by month of symptom onset, Valencian Community, Spain, 1 March 2015–29 February 
2016 (n = 22)
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during the 10 previous years, precedent of whooping 
cough vaccine during the 10 previous years, immi-
grant background, level of education (low: elementary 
school; middle: secondary school; high: university) and 
employment status (employed vs unemployed); (iii) 
Environmental covariates: number and age of relatives 
in the household, number of them at school, smoking 
habits of the parents at home.
Simple and adjusted odds ratios (OR) were calculated 
by means of logistic conditional regression. Simple OR 
were first calculated. Variables potentially associated 
with pertussis in the newborn (i.e. with a p value < 0.10) 
were subsequently entered in a stepwise multivariate 
model, in which the variable with lowest p value at 
each step was removed, to produce a final model. 
The vaccine effectiveness (VE) was calculated as 
1 − OR. Estimations and 95% confidence intervals were 
obtained using the STATA version 12 package.
To investigate how the VE varies depending on the set-
ting from where controls were recruited, the VE was 
also calculated (i) with cases and controls paired by 
paediatrician/family doctor practice, or (ii) with cases 
and controls paired by maternity ward/clinic. Cases are 
the same in each sub-analysis, but their matched con-
trols either originated only from the paediatric/family 
doctor practice where cases presented for treatment, 
or only from the maternity clinic where cases were 
born. When sample size was limited, exact methods of 
logistic regression stratifying for number of pair were 
applied.
In order to examine with more detail a possible inter-
action effect between breastfeeding and vaccination, a 
stratified analysis was carried out.
Ethical issues
Informed consent was obtained from all participants 
before the interview. The principal researcher consulted 
with the Ethics Committee of the Health Department of 
the Valencian Community, which approved the study.
Results
All cases took part in our study. One control from the 
maternity group did not participate and was replaced 
with another one chosen among infants who had 
consulted at same paediatrician/family doctor prac-
tice as the case it was paired with. Moreover, during 
Figure 2
Vaccine effectiveness and 95% confidence interval in function of the origin of the controls, Valencian Community, Spain, 1 
March 2015–29 February 2016 (n = 88)
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the process of identifying controls, between two and 
three control infants per case were excluded on the 
basis of recent cough/bronchiolitis according to clini-
cal records. However, subsequent to these exclusions, 
we could still interview three controls for each case (66 
controls). 
Characteristics of participants
Overall a total of 22 cases were identified, most of 
them during the first half of the study period (Figure 1).
Of 22 cases, 18 were hospitalised. The mean of age of 
cases was 46 days (range 10 to 82 days). The demo-
graphic characteristics and the OR estimated for 
Table 1
Characteristics of the participantsa in the case–control study to assess the effectiveness of pertussis vaccination during 
pregnancy on newborns, and univariate analysis results, Valencian Community, Spain, 1 March 2015–29 February 2016 
(n = 88 participants)
Characteristic Cases (n = 22)
Controls 
(n = 66)
OR simple 
(95% CI) P value
b
Mother vaccinated 5 41 0.080(0.017 to 0.371) 0.001
Sex (girls) 10 29 0.932  (0.331 to 2.62) 0.895
Birthweight mean (g) 3,291 3,180 1.001  (0.999 to 1.002) 0.226
Birthweight <2,500 g 2 1 0.166  (0.015 to 1.83) 0.143
Gestation weeks at birth (mean) 38.4 38.7 0.868  (0.634 to 1.19) 0.378
Apgar <10 (percentage) 10 23 1.69  (0.576 to 4.94) 0.339
Feeding
Infant formula 11 17 1 NA
Mixed feeding 4 9 0.646  (0.158 to 2.64) 0.543
Breastfeeding 7 40 0.227  (0.066 to 0.775) 0.018
Breastfeeding (yes/no)c 7/15 40/26 0.259  (0.081 to 0.832) 0.023
Foreign mother 3 9 1.00  (0.202 to 4.95) 1.000
Mother‘s age: mean (years) 32.6 33.4 0.968  (0.878 to 1.07) 0.521
Educational leveld 14 24 3.04  (1.10 to 8.43) 0.033
Mother’s positione 8 27 0.834  (0.714 to 2.19) 0.714
Mean number of cohabitants in the participant’s household 3.14 2.73 1.45  (0.914 to 2.31) 0.114
Mean number of adults (>14 years-old) cohabiting in the participant’s household 2.14 2.08 1.17  (0.518 to 2.66) 0.701
Mean number of 10–14 year-olds cohabiting in the participant’s household 0.18 0.14 1.32  (0.408 to 4.28) 0.641
Mean number of 5–9 year-olds cohabiting in the participant’s household 0.32 0.21 1.41  (0.608 to 3.26) 0.424
Mean number of 0–4 year-olds cohabiting in the participant’s household 0.50 0.26 2.76  (0.994 to 7.67) 0.051
Schoolchildren of 3–11 years-old cohabiting with the participant in the 
participant’s household 16 32
4.34  
(1.13 to 16.6) 0.032
Habit of smoking at home 3 8 1.14  (0.276 to 4.75) 0.853
CI: confidence interval; NA: not applicable.
a Participants included newborns unvaccinated for pertussis, who were less than 3 months-old.
b Comparison was done by conditional logistics regression.
c Yes: exclusively breastfeeding; No: mixed feeding (formula and breastfeeding) or formula feeding.
d Reference for equation: middle–low.
e Reference for equation: unemployed mother.
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variables hypothesised to be associated with pertussis 
are shown in Table 1.
Mothers of five cases compared to mothers of 41 con-
trols were vaccinated. All vaccinated women had their 
vaccine administered between weeks 28 and 36 of 
gestation, and 15 to 89 days before childbirth. The 
proportion of vaccinated mothers increased during the 
study period from 24 of 59 in the first half of the study 
to 22 of 29 at the end (p value = 0.003). No mother 
had been vaccinated or affected by whooping cough 
during the previous 10 years. Among highly educated 
mothers 31 of 50 were vaccinated; among low, 15 of 
38 (p value = 0.030). Among highly educated mothers, 
30 of 50 were breastfeeding; among low, 17 of 38 (p 
value = 0.197).
The simple OR of vaccination in pregnancy was 0.080 
(95% confidence interval (CI): 0.017 to 0.371). Other 
variables with statistically significant association 
were: breastfeeding, level of education and presence 
of children under 15 years-old in the home.
Adjusting by these variables at the beginning (Model 1, 
Table 2) and eliminating those which lost statistical sig-
nificance, only vaccination and breastfeeding remained 
related with the protection against whooping cough 
(Model 3, Table 2). The adjusted VE did not change sub-
stantially, being 90.9% (95% CI: 56.6 to 98.1) for the 
final model. The interaction between vaccination and 
breastfeeding in the model with both variables was 
not significant (p value = 0.132). The replacement of the 
variable breastfeeding by a dummy variable with three 
categories did not modify the results.
Results obtained from the sub-studies with controls 
who only originated from the same paediatrician/fam-
ily doctor practice as the cases, or with controls only 
coming from the maternity clinics where the cases 
were born, also showed a protective effect of vacci-
nation but with small differences between them. The 
conditional model in the maternity subgroup did not 
converge, due to small sample size, and does not give 
ORs (Figure 2).
In spite of the fact that the interaction between vaccine 
and type of feeding in the whole sample was not sta-
tistically significant, we carried out an analysis taking 
as reference newborns with non-vaccinated mothers 
and artificial feeding, excluding newborns with mixed 
feeding (13 children) as shown in Table 3. Mother vac-
cination during pregnancy has a VE of 95.4% and the 
VE improves slightly with breastfeeding, i.e. to 96.7%.
Finally we observed a protective effect of the breast-
feeding among children from non-vaccinated mothers, 
i.e. a VE of 83.4%, but with wide confidence intervals.
Discussion
Two aspects stand out in this study: First and more 
importantly, we have observed a high effectiveness of 
the pertussis vaccine. Around 90% of the cases in new-
borns under 3 months-old might be avoided by vacci-
nating their mother in the third trimester of pregnancy. 
Second, the results also suggest a possible protective 
effect of breastfeeding in the absence of vaccination.
The magnitude of the VE in this study is in agreement 
with two previous studies, which report VEs of 91% [10] 
and 93% [9]. Armirthalingam et al. [10] found a VE of 
only 38% when they restricted their analysis to vacci-
nated mothers 0–6 days before childbirth or 1–13 days 
later. In our study all the mothers were vaccinated at 
least 2 weeks before the childbirth.
We had complete information on all the cases selected 
for the study and their paired controls, which allowed 
us to analyse by conditional logistic regression. Our 
results showed a strong protective effect of maternal 
Table 2
Result of successive multivariate analysis of potential factors associated with pertussis in newborns, Valencian Community, 
Spain, 1 March 2015–29 February 2016 (n = 88) 
Characteristic
Model 1a Model 2a Model 3a
Adjusted OR 
(95% CI) P value
Adjusted OR 
(95% CI) P value
Adjusted OR 
(95% CI) P value
Mother vaccinated 0.127  (0.025 to 0.658) 0.014
0.116  
(0.024 to 0.567) 0.007
0.091  
(0.019 to 0.434) 0.003
Breastfeeding 0.365  (0.095 to 1.40) 0.141
0.350  
(0.092 to 1.32) 0.121
0.301  
(0.079 to 1.15) 0.080
Schoolchildren in the householdb 2.17  (0.397 to 11.9) 0.370
2.44  
(0.484 to 12.3) 0.280 NA
a NAa
Educational levelc 1.33  (0.347 to 5.13) 0.675 NA
a NAa NAa NAa
NA: not applicable.
a The variable with the highest p value in each consecutive model (1, 2, etc.), was removed in the next model.
b Schoolchildren include children aged 3 to 11 years.
c Reference for equation: middle–low.
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vaccination once adjusted for type of feeding of the 
newborn, without observing a degree of substantial 
confounding from other variables. The estimations of 
the VE obtained with conventional methods of uncon-
ditional logistic regression were slightly lower (data not 
shown).
We agree with Dabrera et al. [9] that the estimated 
effectiveness could be a combination of direct biologi-
cal effect, produced by the antibodies that the mother 
transfers to her child, with the indirect protection due 
to the reduction of the risk of domiciliary transmission 
from the mother who is protected against whooping 
cough. The possible protective effect of breastfeed-
ing may originate from natural components of breast 
milk or specific anti-PT IgA produced by the mother as 
a result of vaccination, since concentration is high in 
colostrum and lasts at least until the eighth week post-
partum [11].
We acknowledge that there are limitations of our obser-
vational study, since the comparability of the groups 
could be compromised. The mothers who choose to be 
vaccinated can present features different from those 
who do not do it [12]. In fact, the women who got vac-
cinated during pregnancy, tended to also follow the 
vaccination schedule more thoroughly for their previ-
ous children too. This could introduce a protection bias 
following the effect of maternal vaccination. In order to 
control for confounding, several multivariate sequen-
tial analyses were carried out. According to the study 
of Quinn et al. [13], exposure to cohabiting school chil-
dren and level of educational attainment of mothers 
were associated with whooping cough in infants. In our 
study, this was only observed in the simple analysis, 
but not in the multivariate one. There could be other 
confounders that we have not evaluated. Among them 
could be the maternal antibody level at the beginning 
of pregnancy [14], or some genetic polymorphisms 
linked with vitamin D [15].
With regard to the eventual modification of effect influ-
enced by the type of feeding, it would be necessary to 
have a sufficient number of children in every stratum 
to analyse this aspect with more precision. Our results 
suggests that breastfeeding should be a factor to be 
considered in the future, in other studies with a larger 
sample size and this starting hypothesis.
In this study, all unvaccinated cases less than 3 months-
old, who were notified to the AVE, were included, gen-
erally covering the whole autonomous community. 
We cannot exclude some bias in case ascertainment, 
because milder cases are frequently missed by health-
care systems. In our study, 18 of the 22 reported cases 
were hospitalised, reflecting the high proportion of 
infants diagnosed with pertussis who are treated at the 
hospital. The response rate in our study was 100%, so 
we believe that there is no risk of bias of selection by 
non-response.
An interesting aspect is that, a progressive decrease 
of the incidence of cases in children less than 3 
months-old was observed (16 of 22 cases in the first 
half of the year) along the study period. This could be 
consequence of the gradual vaccination programme 
implementation in pregnant women during the period, 
supporting the hypothesis of its effectiveness. But in 
the absence of data from other age groups, this evolu-
tion cannot be directly attributed to vaccination. Also, 
the duration of the study, one year, does not allow to 
rule out a seasonal effect.
We think that the robustness of the study rests on the 
quality of the information from principal variables. All 
cases were confirmed by clinical microbiological tests. 
Recent medical records were reviewed for controls 
avoiding children with whooping cough symptoms, 
among those not diagnosed. For both mothers of cases 
and controls vaccination status was verified and the 
dates of vaccine administration were obtained.
In spite of existing limitations, we believe that our 
findings offer results with sufficient internal valid-
ity, the results agree with other published papers and 
have biological plausibility. We have observed, while 
Table 3
Assessment of vaccine effectiveness in function of breastfeeding or artificial feeding by means of conditional logistic 
regression model, Valencian Community, Spain, 1 March 2015–29 February 2016 (n = 75)
Vaccine status of mother and type of feeding Cases (n = 18)
Controls 
(n = 57)
OR 
(95% CI) P value Effectiveness (95% CI)
Non-vaccinated and artificial feeding 9 6 1 Ref Ref
Non-vaccinated and breastfeeding 4 15 0.166  (0.017 to 1.65) 0.126
83.4%  
(-65 to 98.3)
Vaccinated and artificial feeding 2 11 0.046  (0.003 to 0.639) 0.022
95.4%  
(36.1 to 99.7)
Vaccinated and breastfeeding 3 25 0.033  (0.003 to 0.361) 0.005
96.7%  
(63.9 to 99.7)
CI: confidence interval; OR: odds ratio; ref: reference.
Newborns with mixed feeding excluded.
7www.eurosurveillance.org
reducing several of the possible biases, a robust asso-
ciation between vaccination during pregnancy and 
whooping cough.
Our results, from an external validity perspective, could 
be implemented for pertussis prevention in infants less 
than 3 months-old. We have neither investigated effec-
tiveness on a middle or long-term in older children, nor 
possible interference of the mother’s vaccination when 
children will be vaccinated with three doses during the 
first year of life (2, 4 and 6 months-old) [16].
Finally, at a time in which whooping cough presents 
new epidemiological features and new challenges for 
its control [17], our study, together with others recently 
published in other contexts [18-20], provide enough 
evidence in favour of the implementation of vaccina-
tion programmes for pregnant women in order to pre-
vent whooping cough in infants.
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